Abstract
Among the idiopathic inflammatory myopathies (IIM), disease activity relates to the inflammatory manifestations of illness in the muscles, skin, lungs, joints, and other systems that are reversible with treatment, whereas disease damage relates to irreversible changes and long-term side effects of medication and comorbid conditions that have accumulated over time. Most patients with IIM have a combination of active disease and damage. Disease activity and damage may be discordant in different organs at any point in time. There are multiple modalities to assess disease activity and damage including muscle strength and functional testing, serum muscle enzymes, imaging, muscle biopsy, electromyographic findings, extra-muscular symptoms, and skin findings. In the assessment of IIM, muscle strength and physical function are key components but, by themselves, cannot distinguish active disease and damage. While serum levels of muscle enzymes can discriminate active disease from damage or remission and correlate relatively well with disease activity in some IIM subgroups, such as polymyositis and necrotizing myopathies, they do not correlate well with muscle strength, endurance, or physical function in many patients. Magnetic resonance imaging of proximal muscles can demonstrate areas of muscle edema, suggesting muscle inflammation, and areas of muscle atrophy, fatty replacement, or fibrosis, reflecting chronic changes. Occasionally further testing that reveals an irritable electromyogram or muscle biopsy findings of inflammation is required to demonstrate active disease. Dyspnea may be related to pulmonary and non-pulmonary etiologies with difficulty ascertaining active lung inflammation from chronic fibrosis. A comprehensive evaluation utilizing echocardiography, high-resolution chest computed tomography, and respiratory physiology at rest and during exercise is often required. Most skin manifestations are signs of either disease activity (e.g., erythema) or disease damage such as cutaneous scarring. A careful skin examination can distinguish active disease from damage. Tender and swollen joints are often a sign of active arthritis that can be seen in some subsets of myositis like the anti-synthetase syndrome. Often a combination of modalities is most appropriate to assess disease activity and disease damage in individual IIM patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford). 2001;40:1262–73.
Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res. 2011;63(Suppl 11):S118–57.
Rider LG. Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies. Rheum Dis Clin N Am. 2002;28:935–77.
Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K, et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res. 2010;62:465–72.
Peloro TM, Miller OF 3rd, Hahn TF, Newman ED. Juvenile dermatomyositis: a retrospective review of a 30-year experience. J Am Acad Dermatol. 2001;45:28–34.
Volochayev R, Csako G, Wesley R, Rider LG, Miller FW. Laboratory test abnormalities are common in polymyositis and dermatomyositis and differ among clinical and demographic groups. Open Rheumatol J. 2012;6:54–63.
Srikanthan P, Karlamangla AS. Muscle mass index as a predictor of longevity in older adults. Am J Med. 2014;127:547–53.
Day J, Patel S, Limaye V. The role of magnetic resonance imaging techniques in evaluation and management of the idiopathic inflammatory myopathies. Semin Arthritis Rheum. 2017;46:642–9.
Colafrancesco S, Priori R, Valesini G. Inflammatory myopathies and overlap syndromes: update on histological and serological profile. Best Pract Res Clin Rheumatol. 2015 Dec;29(6):810–25.
Wedderburn LR, Varsani H, Li CK, Newton KR, Amato AA, Banwell B, et al. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum. 2007;57:1192–201.
Pugdahl K, Johnsen B, Tankisi H, Camdessanché JP, de Carvalho M, Fawcett PR, et al. Added value of electromyography in the diagnosis of myopathy: a consensus exercise. Clin Neurophysiol. 2017;128:697–701.
Miller SA, Glassberg MK, Ascherman DP. Pulmonary complications of inflammatory myopathy. Rheum Dis Clin N Am. 2015;41:249–62.
Kalluri M, Oddis CV. Pulmonary manifestations of the idiopathic inflammatory myopathies. Clin Chest Med. 2010;31:501–12.
Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Aihara K, et al. The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med. 2013;107:745–52.
Lega JC, Reynaud Q, Belot A, Fabien N, Durieu I, Cottin V. Idiopathic inflammatory myopathies and the lung. Eur Respir Rev. 2015 Jun;24(136):216–38.
Anyanwu CO, Fiorentino DF, Chung L, Dzuong C, Wang Y, Okawa J, et al. Validation of the cutaneous dermatomyositis disease area and severity index: characterizing disease severity and assessing responsiveness to clinical change. Br J Dermatol. 2015;173:969–74.
Lefèvre G, Meyer A, Launay D, Machelart I, DeBandt M, Michaud J, et al. Club Rhumatismes, Inflammation. Seronegative polyarthritis revealing antisynthetase syndrome: a multicentre study of 40 patients. Rheumatology (Oxford). 2015;54(5):927–32.
Meyer A, Lannes B, Goetz J, Echaniz-Laguna A, Lipsker D, Arnaud L, et al. Inflammatory myopathies: a new landscape. Joint Bone Spine. 2018;85(1):23–33.
Hall JC, Casciola-Rosen L, Samedy LA, Werner J, Owoyemi K, Danoff SK, Christopher-Stine L. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken). 2013 Aug;65(8):1307–15.
Tse S, Lubelsky S, Gordon M, Al Mayouf SM, Babyn PS, Laxer RM, et al. The arthritis of inflammatory childhood myositis syndromes. J Rheumatol. 2001;28(1):192–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Curiel, R., Rider, L.G. (2020). Distinguishing Disease Activity and Damage in Myositis. In: Aggarwal, R., Oddis, C. (eds) Managing Myositis. Springer, Cham. https://doi.org/10.1007/978-3-030-15820-0_35
Download citation
DOI: https://doi.org/10.1007/978-3-030-15820-0_35
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-15819-4
Online ISBN: 978-3-030-15820-0
eBook Packages: MedicineMedicine (R0)